COM701 + BMS-986207 + nivolumab

This is a combination immunotherapy regimen consisting of three investigational and approved immune checkpoint inhibitors for the treatment of advanced solid tumors, including platinum-resistant ovarian cancer and endometrial cancer. COM701 is a first-in-class monoclonal antibody that targets PVRIG, an inhibitory receptor on T cells and natural killer (NK) cells, leading to enhanced activation of these immune cells. BMS-986207 (also known as Renvistobart) is an investigational human monoclonal antibody targeting TIGIT, another inhibitory receptor on T cells. Nivolumab (Opdivo) is an approved PD1 inhibitor that blocks the programmed death 1 pathway to promote antitumor immunity. The rationale for combining these agents is to achieve more comprehensive inhibition of the DNAM axis in the tumor microenvironment by simultaneously blocking PVRIG, TIGIT, and PD1 pathways—potentially overcoming resistance mechanisms seen with single-agent checkpoint blockade[1][3][5]. This triplet regimen has shown favorable safety/tolerability profiles in early-phase clinical trials and demonstrated preliminary antitumor activity in heavily pretreated patients with advanced solid tumors[2][3][7].

Other names

anti-TIGIT monoclonal antibody (for BMS-986207)anti-PVRIG monoclonal antibody (for COM701)